Actively Recruiting
A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants
Led by AbCellera Biologics Inc. · Updated on 2026-03-23
40
Participants Needed
1
Research Sites
87 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to assess the safety and tolerability of ABCL575 in healthy participants following single ascending dose (SAD), in comparison to a placebo
CONDITIONS
Official Title
A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy male or female aged 18 to 65 years at screening
- Good general health based on medical history and physical exam
- Body weight between 50 and 100 kilograms
- Body mass index (BMI) between 18.5 and 30.0 kg/m2
- Non-smoker or ex-smoker who stopped nicotine use at least 180 days before dosing
- Either able to have children and agree to use contraception through the study or unable to have children
- Males agree not to donate sperm, females agree not to donate or retrieve eggs from dosing through the end of study
You will not qualify if you...
- Pregnancy or breastfeeding
- Pulse rate below 50 or above 100 beats per minute, or blood pressure below 90/50 mmHg or above 140/90 mmHg
- Estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2
- Severe allergic reactions like angioedema to any drugs
- Significant gastrointestinal, liver, or kidney disease or surgery affecting drug absorption
- History of serious cardiovascular, lung, blood, neurological, psychiatric, endocrine, immune, or skin diseases
- Multiple or severe drug allergies
- Any active bacterial, viral, or fungal infection
- Skin damage such as burns or dermatitis
- History of fainting, palpitations, or unexplained dizziness
- Use of prescription drugs (except hormonal contraceptives or hormone replacement therapy) within 28 days before dosing
- Use of over-the-counter products within 7 days or 5 half-lives before dosing
- Live vaccines within 5 weeks before screening or planned live vaccines within 180 days after dosing
- History of latent or active tuberculosis
- History of shingles or shingles vaccination within 28 days before screening or planned during study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Altasciences Company Inc.
Mount Royal, Quebec, Canada, H3P 3P1
Actively Recruiting
Research Team
C
Clinical Trial Coordinator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here